Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rongfeng Chen

Showing results (71-80 of 72) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 72 results.
Journal of Medicinal Chemistry|August 31, 2021
AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2Frank Narjes, Antonio Llinas, Stefan von Berg, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2024
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2Heike Schönherr, Pelin Ayaz, Alexander M Taylor, et al.
Pageof 8

Showing results (71-80 of 72) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 72 results.
Journal of Medicinal Chemistry|August 31, 2021
AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2Frank Narjes, Antonio Llinas, Stefan von Berg, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 1, 2024
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2Heike Schönherr, Pelin Ayaz, Alexander M Taylor, et al.
Pageof 8